Shares JUNO THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • December 9th, 2014 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
JUNO THERAPEUTICS, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT NOTICE OF GRANT OF RESTRICTED STOCK UNITSRestricted Stock Unit Award Agreement • December 9th, 2014 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Grant of Restricted Stock Units (the “Notice of Grant”), the Terms and Conditions of Restricted Stock Unit Grant, and any appendices and exhibits attached thereto (all together, the “Award Agreement”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 9th, 2014 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
JUNO THERAPEUTICS, INC. FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 5, 2014Investors’ Rights Agreement • December 9th, 2014 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Fourth Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of December 5, 2014, and is between Juno Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A (each, an “Investor” and collectively, the “Investors”).
